Buse, John B.

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 848

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 712

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 699

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

Buse, J. B. (2007) · The American Journal of Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 661

Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs

Yu, J., Wang, J., Zhang, Y., Chen, G., Mao, W., Ye, Y., Kahkoska, A. R., Buse, J. B., Langer, R., & Gu, Z. (2020) · Nature Biomedical Engineering

Advancements in Transdermal Drug DeliveryDiabetes Management and Research

Cited by 604

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 599

Efficacy and safety of degludec versus glargine in type 2 diabetes.

Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 574

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study

Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 565

Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial

Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 543

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 506

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 487

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 420

Effects of sotagliflozin added to insulin in patients with type 1 diabetes

Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 417

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 416

Epidemiologic relationships between A1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial

Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 406

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 402

International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors

Danne, T., Garg, S., Peters, A. L., Buse, J. B., Mathieu, C., Pettus, J. H., Alexander, C. M., Battelino, T., Ampudia-Blasco, F. J., Bode, B. W., et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 379

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-Term Pharmacokinetic and 12-Week Dose-Ranging Studies

Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 325

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 316

Quality of Diabetes Care in U.S. Academic Medical Centers

Grant, R. W., Buse, J. B., Meigs, J. B., & for the University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team (2005) · Diabetes Care

Diabetes Management and EducationDiabetes Management and Research

Cited by 311

Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.

Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 300

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis

Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet

Health Systems, Economic Evaluations, Quality of LifeHealth Promotion and Cardiovascular Prevention

Cited by 287

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 279

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial

Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 273